DrugPatentWatch Database Preview
Details for Patent: 10,258,637
» See Plans and Pricing
Which drugs does patent 10,258,637 protect, and when does it expire?
Patent 10,258,637 protects SYNJARDY XR, TRIJARDY XR, GLYXAMBI, JARDIANCE, and SYNJARDY, and is included in five NDAs.
This patent has thirty-one patent family members in twenty-four countries.
Summary for Patent: 10,258,637
Title: | Pharmaceutical composition, methods for treating and uses thereof |
Abstract: | The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD). |
Inventor(s): | Broedl; Uli Christian (Mainz am Rhein, DE), Macha; Sreeraj (Basking Ridge, NJ), von Eynatten; Maximilian (Wiesbaden, DE), Woerle; Hans-Juergen (Grandvaux, CH) |
Assignee: | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) |
Application Number: | 15/918,401 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,258,637 |
Patent Claim Types: see list of patent claims | Use; Delivery; |
Drugs Protected by US Patent 10,258,637
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Boehringer Ingelheim | SYNJARDY XR | empagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208658-001 | Dec 9, 2016 | RX | Yes | No | Start Trial | Start Trial | Start Trial | |||||
Boehringer Ingelheim | SYNJARDY XR | empagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208658-002 | Dec 9, 2016 | RX | Yes | No | Start Trial | Start Trial | Start Trial | |||||
Boehringer Ingelheim | SYNJARDY XR | empagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208658-003 | Dec 9, 2016 | RX | Yes | No | Start Trial | Start Trial | Start Trial | |||||
Boehringer Ingelheim | SYNJARDY XR | empagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208658-004 | Dec 9, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||||
Boehringer Ingelheim | TRIJARDY XR | empagliflozin; linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 212614-001 | Jan 27, 2020 | RX | Yes | No | Start Trial | Start Trial | Start Trial | |||||
Boehringer Ingelheim | TRIJARDY XR | empagliflozin; linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 212614-002 | Jan 27, 2020 | RX | Yes | No | Start Trial | Start Trial | Start Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,258,637
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2014247092 | Start Trial | |||
Canada | 2812519 | Start Trial | |||
Canada | 2908635 | Start Trial | |||
Chile | 2015002940 | Start Trial | |||
China | 105377267 | Start Trial | |||
China | 109893534 | Start Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |